Kappa-type opioid receptor

Description:

Description
  • Accession: P33534
  • Swissprot: OPRK_MOUSE
  • Organism: Mus musculus
  • Gene: Oprk1
  • Target class: GPCR

Drug Relations:

ketobemidone
Bioactivity details MOA
levorphanol
A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection. Bioactivity details MOA
morphine
The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Bioactivity details MOA
nalbuphine
A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS. Bioactivity details MOA
nalfurafine
Bioactivity details MOA
nalorphine
A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete. Bioactivity details MOA
naloxone
A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. Bioactivity details MOA
naltrexone
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Bioactivity details MOA
oxycodone
A semisynthetic derivative of CODEINE. Bioactivity details MOA
pethidine
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. Bioactivity details MOA